Olaratumab: PDGFR-Î± inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

Antonio Russo; Giuseppe Badalamenti; Francesco Pantano; Massimo Aglietta; Andrea Napolitano; Antonio Russo; Mariella Spalato Ceruso; Giuseppe Badalamenti; Bruno Vincenzi; Giovanni Grignani; Giuseppe Tonini; Daniele Santini; Daniele Santini

Olaratumab: PDGFR-Î± inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

Antonio Russo, Giuseppe Badalamenti, Francesco Pantano, Massimo Aglietta, Andrea Napolitano, Antonio Russo, Mariella Spalato Ceruso, Giuseppe Badalamenti, Bruno Vincenzi, Giovanni Grignani, Giuseppe Tonini, Daniele Santini, Daniele Santini

Discipline Chirurgiche, Oncologiche e Stomatologiche

Risultato della ricerca: Article › peer review

11 Citazioni (Scopus)

Abstract

Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-Î± by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-Î± inhibition in the therapy of advanced soft tissue sarcomas.

Lingua originale	English
pagine (da-a)	1-6
Numero di pagine	6
Rivista	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume	118
Stato di pubblicazione	Published - 2017

All Science Journal Classification (ASJC) codes

???subjectarea.asjc.2700.2717???
???subjectarea.asjc.2700.2720???
???subjectarea.asjc.2700.2730???

Altri file e collegamenti

Cita questo

@article{451b5edf13914d86bc9726765794d9f8,

title = "Olaratumab: PDGFR-{\^I}± inhibition as a novel tool in the treatment of advanced soft tissue sarcomas",

abstract = "Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-{\^I}± by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-{\^I}± inhibition in the therapy of advanced soft tissue sarcomas.",

keywords = "Doxorubicin, Geriatrics and Gerontology, Hematology, Olaratumab, Oncology, PDGFR-{\^I}±, Soft tissue sarcomas, Doxorubicin, Geriatrics and Gerontology, Hematology, Olaratumab, Oncology, PDGFR-{\^I}±, Soft tissue sarcomas",

author = "Antonio Russo and Giuseppe Badalamenti and Francesco Pantano and Massimo Aglietta and Andrea Napolitano and Antonio Russo and {Spalato Ceruso}, Mariella and Giuseppe Badalamenti and Bruno Vincenzi and Giovanni Grignani and Giuseppe Tonini and Daniele Santini and Daniele Santini",

year = "2017",

language = "English",

volume = "118",

pages = "1--6",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Olaratumab: PDGFR-Î± inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

AU - Russo, Antonio

AU - Badalamenti, Giuseppe

AU - Pantano, Francesco

AU - Aglietta, Massimo

AU - Napolitano, Andrea

AU - Russo, Antonio

AU - Spalato Ceruso, Mariella

AU - Badalamenti, Giuseppe

AU - Vincenzi, Bruno

AU - Grignani, Giovanni

AU - Tonini, Giuseppe

AU - Santini, Daniele

PY - 2017

Y1 - 2017

N2 - Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-Î± by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-Î± inhibition in the therapy of advanced soft tissue sarcomas.

AB - Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-Î± by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-Î± inhibition in the therapy of advanced soft tissue sarcomas.

KW - Doxorubicin

KW - Geriatrics and Gerontology

KW - Hematology

KW - Olaratumab

KW - Oncology

KW - PDGFR-Î±

KW - Soft tissue sarcomas

KW - Doxorubicin

KW - Geriatrics and Gerontology

KW - Hematology

KW - Olaratumab

KW - Oncology

KW - PDGFR-Î±

KW - Soft tissue sarcomas

UR - http://hdl.handle.net/10447/246543

UR - http://www.elsevier.com/locate/critrevonc

M3 - Article

VL - 118

SP - 1

EP - 6

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -

Olaratumab: PDGFR-Î± inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

Abstract

All Science Journal Classification (ASJC) codes

Altri file e collegamenti

Fingerprint

Cita questo